Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis

被引：0
|
作者：
Riederer, M. A. [1 ]
Crescence, L. [2 ]
Caroff, E. [1 ]
Hubler, F. [1 ]
Panicot-Dubois, L. [2 ]
Dubois, C. [2 ]
机构：
[1] Idorsia Pharmaceut Ltd, Allschwil, Switzerland
[2] Aix Marseille Univ, INSEAM 1263, INRAE 1260, C2VN, Marseille, France
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3819 / 3819
页数：1
相关论文
共 50 条
  • [1] The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration
    Baumann, Martine
    Lack, Benoit
    Guillaumat, Isabelle
    Murphy, Mark J.
    Riederer, Markus A.
    PLATELETS, 2022, 33 (01) : 147 - 156
  • [2] The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo
    Crescence, Lydie
    Kramberg, Markus
    Baumann, Martine
    Rey, Markus
    Roux, Sebastien
    Panicot-Dubois, Laurence
    Dubois, Christophe
    Riederer, Markus A.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (22)
  • [3] Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist
    Parker, William A. E.
    Storey, Robert F.
    EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (01) : 1 - 6
  • [4] Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
    Schilling, Uta
    Hsin, Chih-Hsuan
    Delahaye, Stephane
    Krause, Andreas
    Wuelfrath, Hauke
    Halabi, Atef
    Dingemanse, Jasper
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (08): : 1906 - 1915
  • [5] Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist
    Anderson, Shawn D.
    Shah, Niren K.
    Yim, Juwon
    Epstein, Benjamin J.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (03) : 524 - 537
  • [6] Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model
    Crescence, Lydie
    Darbousset, Roxane
    Caroff, Eva
    Hubler, Francis
    Riederer, Markus A.
    Panicot-Dubois, Laurence
    Dubois, Christophe
    THROMBOSIS RESEARCH, 2021, 200 : 133 - 140
  • [7] Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists
    Henrich, Andrea
    Claussen, Christian Hove
    Dingemanse, Jasper
    Krause, Andreas
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (07): : 735 - 747
  • [8] Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor
    Beavers, Craig J.
    Effoe, Samuel. Aaron
    Dobesh, Paul P.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 79 (02) : 161 - 167
  • [9] Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects
    Ufer, Mike
    Huynh, Christine
    van Lier, Jan Jaap
    Caroff, Eva
    Fischer, Hartmut
    Dingemanse, Jasper
    XENOBIOTICA, 2020, 50 (04) : 427 - 434
  • [10] Comparison of the effects of the GPIIb-IIIa antagonist Zalunfiban and the P2Y12 antagonist Selatogrel on Platelet Aggregation
    Curry, Benjamin J.
    Rikken, A. O. F. Sem
    Gibson, C. Michael
    Granger, Christopher B.
    van 't Hof, Arnoud W. J.
    ten Berg, Jurrien M.
    Jennings, Lisa K.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2023, 56 (04) : 499 - 510
12345